{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chew KW"],"funding":["National Institute of Allergy and Infectious Diseases","NCATS NIH HHS","NIAID NIH HHS","National Institutes of Health","NIH HHS"],"pagination":["131-136"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11793053"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["231(1)"],"pubmed_abstract":["We explored viral and symptom rebound after coronavirus disease 2019 amubarvimab-romlusevimab monoclonal antibody therapy versus placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal severe acute respiratory syndrome coronavirus 2 polymerase chain reaction testing at study days 3, 7, 14, and 28. Viral rebound was defined as RNA ≥3 and ≥0.5 log10 copies/mL increase from day 3 or 7, and symptom rebound as hospitalization or any moderate/severe symptom for ≥2 days after initial symptom improvement. There was no difference in viral rebound (∼5%/arm) (analysis population n = 713) or symptom rebound among participants who initially improved (hazard ratio, 0.95 [95% confidence interval, .52-1.75]; analysis population n = 574); <1% had both viral/symptom rebound."],"journal":["The Journal of infectious diseases"],"pubmed_title":["Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial."],"pmcid":["PMC11793053"],"funding_grant_id":["U01 AI068636","UM1 AI106701","UM1 AI069424","UM1 AI068634","UM1AI068636","UL1 TR001881","UM1 AI068636","UM1AI068634","UM1 AI069419","UM1AI106701"],"pubmed_authors":["Kosmyna J","Jilg N","McGinley B","Murtaugh W","Evering T","Eron JJ","Patel N","Hughes M","Smith DD","Currier JS","Jennings C","Singh U","Gottesman J","Hosey L","Li J","Riviere C","Beck J","Moser C","Perelson A","Evering TH","Margolis D","Smith DM","Eron J","Fischer W","Wohl DA","Currier J","Giganti M","Daar ES","Fletcher C","Hughes MD","Daar E","Chew KW","Newell M","Sieg S","Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-2/A5401 Study Team, Study Sites, and Investigators","Gapara M","Chew K","Corado K","Wohl D","Taiwo B","Jagannathan P","Rwakazina I","Li JZ","Ritz J","Javan AC","Shahkolahi A","Colsh K","Pillay S","Cardoso S","Roa J","Pedersen S","Ignacio RB","Dragavon J","Greenfelder B"],"additional_accession":[]},"is_claimable":false,"name":"Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial.","description":"We explored viral and symptom rebound after coronavirus disease 2019 amubarvimab-romlusevimab monoclonal antibody therapy versus placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal severe acute respiratory syndrome coronavirus 2 polymerase chain reaction testing at study days 3, 7, 14, and 28. Viral rebound was defined as RNA ≥3 and ≥0.5 log10 copies/mL increase from day 3 or 7, and symptom rebound as hospitalization or any moderate/severe symptom for ≥2 days after initial symptom improvement. There was no difference in viral rebound (∼5%/arm) (analysis population n = 713) or symptom rebound among participants who initially improved (hazard ratio, 0.95 [95% confidence interval, .52-1.75]; analysis population n = 574); <1% had both viral/symptom rebound.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-06-04T11:03:00.217Z","creation":"2026-05-08T03:11:06.27Z"},"accession":"S-EPMC11793053","cross_references":{"pubmed":["39400063"],"doi":["10.1093/infdis/jiae501"]}}